Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methicillin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 2/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | LMNA | P02545 | 4/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 4/20 | 0.62 |
| ▸ | HRH1 | P35367 | 1/20 | 0.58 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | RECQL | P46063 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | TEK | Q02763 | 1/20 | 0.56 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | RARB | P10826 | 1/20 | 0.52 |
| ▸ | RARG | P13631 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methicillin SCHEMBL10743888 | 1.00 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL11207170 | 1.00 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL15544897 | 0.99 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL30686387 | 0.99 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL4548766 | 0.99 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL6930787 | 0.99 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL4898 | 0.99 | PTGS1 (1.00) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL28422658 | 0.98 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL29184234 | 0.98 | PTGS1 (0.98) | PTGS1PDE3ALMNAABCB11HRH1 | |
| Methicillin SCHEMBL28861820 | 0.97 | PTGS1 (0.96) | PTGS1PDE3ALMNAABCB11HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3020 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250099557-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2025-03-27 | — | — | US | claimed |
| EP-4374848-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | Shanghai Bao Pharmaceuticals Co., Ltd. (CN) | 2024-05-29 | — | — | EP | claimed |
| CN-117858696-A | Antibiotic pharmaceutical composition capable of subcutaneous administration | 上海宝济药业股份有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-111855619-B | Surface plasma resonance sensing chip, preparation method thereof and sensing equipment | 北京服装学院 | 2023-05-12 | — | — | CN | claimed |
| WO-2023001264-A1 | ANTIBIOTIC PHARMACEUTICAL COMPOSITION CAPABLE OF SUBCUTANEOUS ADMINISTRATION | 上海宝济药业有限公司 | 2023-01-26 | — | — | WO | claimed |
| US-20220362327-A1 | COMPOSITIONS AND METHODS FOR WOUND HEALING | DIAB NASSER (US) | 2022-11-17 | — | — | US | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| CN-113559264-A | Methods of treating microbial infections including mastitis | 罗达制药公司 | 2021-10-29 | — | — | CN | claimed |
| EP-0786999-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1999-01-20 | — | — | EP | claimed |
| EP-0792371-A4 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO INC (US) | 1998-12-30 | — | — | EP | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| EP-0792371-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-09-03 | — | — | EP | claimed |
| EP-0786999-A1 | COMBINATION METHOD FOR ACNE TREATMENT | Merck & Co., Inc. (US) | 1997-08-06 | — | — | EP | claimed |
| US-5543417-A | 5 Alpha-reductase inhibitor and at least one of an antibacterial agent, a keratolytic agent or an anti-inflammatory agent | MERCK & CO., INC. (US) | 1996-08-06 | — | — | US | claimed |
| WO-1996012487-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| WO-1996012817-A1 | COMBINATION METHOD FOR ACNE TREATMENT | MERCK & CO., INC. (US) | 1996-05-02 | — | — | WO | claimed |
| US-4324783-A | SYNERGISTIC COMBINATION OF PENCILLINS | TOYAMA CHEMICAL CO., LTD. (JP) | 1982-04-13 | — | — | US | claimed |
| US-4199566-A | DERIVATIVES OF PENICILLANIC ACID | TOYAMA CHEMICAL COMPANY, LIMITED (JP) | 1980-04-22 | — | — | US | claimed |